Victoria Federico Paly
7PUBLICATIONS
19CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Aug 05, 2024
Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective.Victoria Federico Paly, Shujun Li, Pratishtha Khanduri
|Jul 08, 2024
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US.Victoria Federico Paly, Arvind Dasari, Joleen Hubbard
|Dec 23, 2022
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan Martin
|Aug 02, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.Andrea Gabrio, Necdet B Gunsoy, Gianluca Baio
|Mar 31, 2022
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.Victoria Federico Paly, Murat Kurt, Lirong Zhang
|Oct 01, 2020
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.Victoria Federico Paly, Yusuke Hikichi, Timothy Baker
Pageof 2
Frequent Collaborators
3 joint publications
Afisi S Ismaila
2 joint publications
Alan Martin
2 joint publications
Luis Hernandez
1 joint publications
Gianluca Baio
1 joint publications
David M G Halpin
1 joint publications
Robert A Wise
1 joint publications
Fernando J Martinez
1 joint publications
David A Lipson
1 joint publications
Ian Naya
1 joint publications
Necdet B Gunsoy
